Expansion in biomanufacturing Samsung BioLogics is investing significantly in expanding its biomanufacturing capacity, presenting a sales opportunity for suppliers of biomanufacturing equipment, technology, and services.

Strategic investments in partners Through investments in companies like C2N Diagnostics and collaborations with Biosciences, Samsung BioLogics is forming strategic partnerships, creating avenues for cross-selling and joint business development opportunities.

Participation in industry events By actively participating in renowned industry events such as DCAT Week and J.P.Morgan Healthcare Conference, Samsung BioLogics is signaling its openness to new partnerships and solutions, making it a prime target for networking and sales engagements.

Focus on antibody-drug conjugates With a focus on developing antibody-drug conjugate products in collaboration with LigaChem Biosciences, Samsung BioLogics presents a niche sales opportunity for companies offering expertise, technologies, or services related to ADC development and production.

Global expansion and market visibility Samsung BioLogics' efforts to expand globally and enhance its market visibility through partnerships and attendance at key events set the stage for sales professionals to engage with a company that is actively seeking innovative solutions and collaborations.